Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Radioimmunotherapy With 90Y-Humanized MN-14 IgG Administered as a Single Dose to Patients With Refractory Advanced/Metastatic Pancreatic Carcinoma
Conditions
Interventions
hMN14 (labetuzumab)
Locations
10
United States
Hoag Cancer Center
Newport Beach, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Bay Pines VA Medical Center
St. Petersburg, Florida, United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
Virginia Mason Medical Center
Seattle, Washington, United States
Medizinische Fakultaet der Charité Berlin
Berlin, Germany
Start Date
January 1, 2000
Completion Date
December 1, 2003
Last Updated
August 19, 2021
NCT07542041
NCT03937453
NCT06885697
NCT04146298
NCT06388967
NCT04291651
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions